Haberman Associates joined Innovalyst as an Affiliate.
Innovalyst is a North Carolina-based consulting consortium. It is led by four Managing Partners with over 20 years of industrial experience as executives at top-tier pharmaceutical or biotechnology companies. Innovalyst’s Intellectual Capital Advisory Network (ICAN) also includes over 75 Affiliates with an extraordinary breadth and depth of life science business skills.
Since 1997, Haberman Associates has been a member of the Biopharmaceutical Consortium (BPC), a Boston-based life science consulting network. We shall continue to maintain our membership in BPC, and our Boston-area location. However, we shall also expand our network to include Innovalyst. In addition to Haberman Associates, another BPC member, Trilogy Associates (headed by Joseph Kalinowski), is both a member of BPC and an Innovalyst Affiliate. Trilogy relocated to North Carolina in 2008.
Haberman Associates will maintain its primary focus on science and technology strategy, and on new product development via internal R&D and partnering. However, we shall be able to draw on our partners in BPC and Innovalyst to form project teams to take on larger, more complex projects requiring multiple areas of expertise, especially for large pharmaceutical and biotechnology companies. We shall also continue to serve life science clients of all sizes, from start-ups to major corporations.
If you have any questions about Haberman Associates and its expanded consulting network, or would like to discuss your company’s needs, please contact us.
Allan B. Haberman, Ph.D. was quoted in an article entitled “Bristol-Myers Squibb swallows last of antibody pioneers”, by Malorye Allison, in the September issue of Nature Biotechnology. The article focused on the monoclonal antibody sector, especially on the recent acquisition of Medarex by Bristol-Myers Squibb.
Our blog is intended to be your place on the Web for discussion of scientific and business issues in the biotechnology, pharmaceutical, diagnostics, and research products industry. People in the industry and in the wider biomedical research community are invited to visit the blog, and to subscribe to and comment on its posts.
Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report,Approaches to Reducing Phase II Attrition, by Allan B. Haberman, Ph.D. This new Insight Pharma Report discusses leading-edge strategies to improve R&D productivity in the pharmaceutical and biotechnology industry, which is arguably the central challenge in the industry today. These strategies, which focus on translational medicine, are aimed at lowering R&D costs and enabling the industry to successfully develop innovative drugs that address unmet medical needs. The report also includes an analysis of the results of an industry survey on strategies to improve R&D productivity, and complete transcripts of expert interviews.
Allan B. Haberman, Ph.D. gave a presentation, entitled “The Therapeutic RNAi Market – Lessons from the Evolution of the Biologics Market” at the conference “Executing on the Promise of RNAi”, Cambridge MA, January 22-23, 2009.
Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, Obesity Drug Pipeline: Developing Therapies for a Complex Disease, by Allan B. Haberman, Ph.D. This new Insight Pharma Report reviews next-generation obesity drugs, including late-stage development programs as well as selected early-stage approaches to developing obesity drugs. It also discusses the obesity drug market, the need for novel drugs that are safe and truly effective, and the challenges in developing and commercializing such drugs.
Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, Blood-Brain Barrier: Bridging Options for Drug Discovery and Development, by Allan B. Haberman, Ph.D. This new Insight Pharma Report reviews novel technologies designed to enable small and large molecule drugs to efficiently cross the blood-brain barrier. The inability of most drugs to cross the blood-brain barrier is a major bottleneck in the development of central nervous system (CNS) drugs, especially novel drugs aimed at major unmet needs in the CNS area, such as Alzheimer’s disease, Parkinson’s disease, ALS, and stroke.
The report will be of special interest to you if you are involved in the research, development, licensing, or portfolio management of current and potential CNS therapeutics. It will also be of interest to you if you are interested in assessing new opportunities in CNS diseases for your company.